CVRx Raises $75M In IPO To Commercialize And Develop Heart Failure Therapy
The funds will support expanded commercialization of the company’s baroreflex activation stimulation technology to treat heart failure in patients with a low left-ventricular ejection fraction.
You may also be interested in...
Ancora Heart will use the new funding to accelerate its pivotal trial of the AccuCinch ventricular restoration system for treating heart failure patients with reduced ejection fraction.
VEO Ophthalmics’ Artificial Iris, Boston Scientific’s Single-Use Duodenoscope Win Pass-Through Payments
US CMS described several products winning device pass-through payment status for 2021 in an outpatient prospective payment system final rule.
The PMA approval is based on the results of the BeAT HF trial, which showed that baroflex activation therapy with Barostim Neo safely improves quality-of-life scores and exercise capacity in patients with heart failure and reduced ejection fraction.